Press Releases

Shanghai, April 3, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced a strategic partnership with Mabsoft Therapeutics, an innovative biopharmaceutical company focused on the discovery of Immuno-Stimulating Antibody Conjugates (ISACs) and novel antibodies, to advance the development of novel ADCs, with a particular focus on innovative ISACs.

The design strategy of ISACs parallels that of ADCs, with a key distinction: ISACs incorporate immune agonists in place of a portion of the cytotoxic payload. These immune agonists are designed to enhance immune system activation, thereby augmenting anti-tumor immunity and improving the clearance of malignant cells.

The partnership marks a strong strategic alliance in the field of next-generation ISAC therapies. Under the agreement, WuXi XDC will provide end-to-end CRDMO service for Mabsoft Therapeutics’s ISAC pipeline, including drug discovery, process development, and GMP manufacturing. This collaboration will leverage WuXi XDC’s cutting-edge bioconjugation platform and industry expertise to accelerate the development of next-generation ISAC therapies.

Dr. Jimmy Li, CEO of WuXi XDC, commented: “This partnership underscores our commitment to pioneering next-generation bioconjugate therapies. By integrating our end-to-end CRDMO capabilities with Mabsoft’s innovative ISAC platform, we aim to accelerate the development of transformative therapies that address unmet patient needs globally.”

Mr. Erdong Hua, Chairman of Mabsoft Therapeutics, stated: “Overcoming tumor resistance has always been at the core of our innovation strategy, and we have built strong expertise in ADC technology. With this partnership, we are expanding our focus to ISACs, a promising new frontier in immuno-oncology. By combining our deep scientific knowledge with WuXi XDC’s world-class CRDMO platform, we aim to accelerate the development of cutting-edge ISAC therapies and drive global innovation in cancer treatment.”

About WuXi XDC

WuXi XDC Cayman Inc.  (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development, and manufacturing services for bioconjugates. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.

Contacts

Investor: wuxixdc.ir@wuxibiologics.com

Media: wuxixdc_pr@wuxibiologics.com

BD: wuxixdc_info@wuxibiologics.com

About Mabsoft Therapeutics

MabSoft Therapeutics Co., Ltd. is an innovative biopharmaceutical company focused on the discovery of Immuno-Stimulating Antibody Conjugates (ISACs) and novel antibodies. With a clinical development goal to “achieve a 30% durable response rate in solid tumors within five years”, the company is dedicated to advancing globally innovative therapeutics for cancer and other major diseases. Currently, MabSoft has multiple innovative drug candidates at various stages within its R&D pipeline.

Contacts: info@mabsoftbio.com